Outsourcing

The BIO convention, and healthcare reform, could re-energize biotech.

Restructuring in the biopharmaceutical industry is renewing a focus on resource optimization.

Growth in the market for monoclonal antibodies, recombinant proteins, and vaccines creates new opportunities for drug companies and suppliers.

Pfizer Invests In Nodality; SOCMA Approves New Members; And More.

Seventeen pharmaceutical markets are now ranked as "pharmerging," according to market-research firm IMS Health.

Merck Ends Partnership With Dynavax; PhRMA Elects Officers; And More.

Abbott Agrees to Acquire Facet Biotech; FDA Issues Black-Box Warning For Plavix; and More.

Exelixis And XenoPort Announce Job Cuts; GSK Dedicates India Facility; And More.

Astellas Pharma Makes Bid for OSI Pharmaceuticals; Ringo Retiring From Pfizer; And More.

CMOs' business model has all of the flaws of the captive model it is meant to replace.

Could President Obama's tax reform, which is targeted at reducing outsourcing, endanger India's contract-services industry?

Emerging markets remain an important element in the strategies of pharmaceutical companies and their suppliers.

Pre-Interphex 2010 Product Releases.

To best carry out the vision of Hatch-Waxman, Congress must act now on biogenerics.

Contract manufacturers report improving business conditions, but will they continue?

Brief pharmaceutical news items for March 2010.

Analysis of the opportunities and challenges in the biosimilars market.

From last-minute product inserts to putting out fires, close calls are a common occurrence.

It's time to maintain a thorough traceable excipient trail.

If both sides of the aisle don't agree on even mild healthcare reform soon, the bill could die out.

The vice-president addresses shifts in process and more.

Pharmaceutical companies and their suppliers share approaches in risk mitigation in sourcing and ways to optimize the outsourced relationship.

The second annual Pharmaceutical Technology Bioprocessing Survey offers a snapshot of the industry following 2009's megamergers.

The author examines the use and advantages of disposable technologies in the fill–finish of sterile pharmaceutical products and how these technologies can reduce costs and time in producing clinical-trial materials.

Merck To Eliminate 15,000 jobs; Tauzin Stepping Down At PhRMA; And More.